In 2014, Medtronic (MDT<\/a> 0.57%), a giant in the medical-device arena, acquired Mazor Robotics, a company focused on spinal surgeries. More recently, it’s been developing its Hugo robot-assisted surgical (RAS) system to tackle procedures typically performed with da Vinci systems.<\/p>\n Strong uptake of da Vinci machines pushed shares of Intuitive Surgical up by about 23,300% since its initial public offering<\/a> (IPO). Here’s a look at what Medtronic’s accomplished recently to see if investors can expect similar gains on the back of the company’s Hugo systems.<\/p>\n How Medtronic is performing against Intuitive Surgical so far<\/p>\n Intuitive Surgical recently reported 10,763 of its da Vinci systems were installed as of Sept. 30, 2025. Worldwide procedures performed using da Vinci systems rose by 19% year over year during the third quarter. Lung tumor biopsies performed with its relatively new Ion system jumped 52% higher year over year.<\/p>\n System sales are significant, but Intuitive makes most of its money from sales of instruments and accessories that must be replaced before each procedure. Intuitive Surgical reported third-quarter sales<\/a> that surged 23% higher year over year to an annualized $10 billion.<\/p>\n Assessing the market performance of Medtronic’s robot-assisted surgical systems isn’t easy. It lumps Mazor-related sales into its cranial and spinal technologies division. Hugo-related sales are folded into a division called surgical and endoscopy. Management still isn’t sharing many details regarding the number of systems installed or how many procedures they’re performing.<\/p>\n During Medtronic’s fiscal first quarter that ended on July 25, 2025, surgical and endoscopy sales rose 4.4%, while cranial and spinal technologies revenue climbed 5.5%. Annualized sales for both divisions climbed to an annualized $11.3 billion.<\/p>\n On the surface, it may seem like Medtronic is competing well against Intuitive Surgical, but this isn’t necessarily the case. The reporting divisions that house Medtronic’s surgical robots contain many non-robotic products. If the company’s share of the surgical-robotics market was growing rapidly, it’s unlikely that management would want to keep those numbers a secret.<\/p>\n Today’s Change<\/p>\n (-0.57%) $-0.54<\/p>\n Current Price<\/p>\n $93.67<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $121B<\/p>\n Day’s Range<\/p>\n $93.29 – $94.96<\/p>\n 52wk Range<\/p>\n $79.29 – $99.37<\/p>\n Volume<\/p>\n 4.3M<\/p>\n Avg Vol<\/p>\n 7M<\/p>\n Gross Margin<\/p>\n 59.81%<\/p>\n Dividend Yield<\/p>\n 0.03%<\/p>\n An uphill battle<\/p>\n In April, Hugo met its goals in a clinical trial that tested its ability to complete urologic procedures, including prostatectomies. The results show Hugo leads to dramatically fewer complications versus old-fashioned, non-robot-assisted surgery, but this won’t necessarily lead to uptake in this arena.<\/p>\n Intuitive’s da Vinci machines perform a lot of urologic procedures, too. So far, it’s hard to say that one system is any better than the other. A recent meta-analysis of eight different studies regarding prostatectomies showed postoperative outcomes, including complications, were statistically similar for patients who were operated on by a da Vinci system or a Hugo system.<\/p>\n Intuitive Surgical’s already existing footprint is an enormous advantage that could prevent Hugo from gaining a large share of the surgical-robotics market. Hospitals that already have one surgical team trained to use a da Vinci system have a strong financial incentive<\/a> to continue choosing Intuitive Surgical for subsequent systems.<\/p>\n![\"Investor](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2025\/10\/investor-thinking-about-stock-charts-getty.jpg\"\/)
<\/p>\n<\/p>\n